University of Technology Sydney
Professor Kelvin Chan was initially trained in Pharmaceutical Industry; further developed in clinical pharmacology, drug metabolism and pharmacokinetics at medical schools in University of Birmingham (PhD & DSc) and University of Liverpool (Post-doctor fellow), United Kingdom, Finders Medical School in Adelaide, Australia and Karolinska Institute in Sweden; started interests in R&D of traditional Chinese medicine since early 1990s at the Chinese University of Hong Kong. He has taught medicinal pharmacology in universities in the UK, Hong Kong, UAE and Australia. Currently he is Visiting Professor of Natural Products and TCM Research at Liverpool John Moores University, UK and Adjunct Professor in TCM Research at University of Technology Sydney and Western University in Australia. He has published 3 specialist books on Chinese medicine, over 600 hundred publications including keynotes/conference presentation, drug monographs, and peer-reviewed papers (259) in conventional medicine and TCM. His present research directions focus on quality control and R&D of Chinese medicines and natural products using technology developed from systems biology, and patient-reported outcomes (PROs) using TCM specific QOL instrument linked with biomedical parameters in clinical studies. He has supervised and co-supervised 34 postgraduates (26 PhD and 8 MSc/MPhil). He is presently member of the following boards/committee: International Advisory Board and Scientific Committee of the Hong Kong Chinese Materia Medica Standards, Department of Health, Hong Kong (Feb 2002 to present); WHO Temporary Advisor on Training Course of Quality Control of Herbal Medicine (2013 to present); Board of Directors of the Good Practice in TCM Research Association (2012 to 2016); Expert at the TCM Working Group of the European Directorate for Quality of Medicine & Healthcare, in Strasbourg on monographs for the Chinese materia medica for the European Pharmacopoeia (March 2010 to 2014); Advisory Board of the Consortium for Globalisation of Chinese Medicine (2010 to Present).
Quality control and R&D of Chinese medicines and natural products